Agios Pharmaceuticals (NASDAQ:AGIO) receives a Neutral rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. maintained its neutral recommendation for the company’s shares Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) in a research report published Thursday morning, Benzinga reports. They currently have a $46.00 price target on shares of this biopharmaceutical company.

Other research analysts have also published research reports on the company. Goldman Sachs Group increased their target price on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a Neutral rating in a report on Tuesday, June 4th. On Wednesday, May 29, StockNews.com upgraded Agios Pharmaceuticals from sell to hold. Royal Bank of Canada increased their target price on Agios Pharmaceuticals from $44.00 to $53.00 and gave the stock an outperform rating in a research report on Tuesday, June 4th. Finally, Cantor Fitzgerald maintained an overperform rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 9th. Three equity research analysts have given the company a hold rating and two have given a buy rating to the company. According to MarketBeat, Agios Pharmaceuticals currently has an average rating of Hold and an average price target of $50.67.

Read our latest report on AGIO

Agios Pharmaceuticals Price Performance

AGIO shares opened Thursday at $46.77. The company’s fifty-day moving average price is $34.71 and its 200-day moving average price is $28.85. Agios Pharmaceuticals has a 1-year low of $19.80 and a 1-year high of $49.06. The company has a market capitalization of $2.66 billion, a PE ratio of -7.40 and a beta of 0.77.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.20. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The company’s revenue for the quarter was $8.19 million, compared to analyst estimates of $8.37 million. In the same quarter last year, the company reported earnings per share ($1.47). Agios Pharmaceuticals’ quarterly revenue increased 46.0% year-over-year. Equities research analysts expect that Agios Pharmaceuticals will post -5.57 earnings per share for the current fiscal year.

Confidential activity

In other news, Director Jacqualyn A. Fouse sold 7,791 shares of the company’s stock on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total value of $214,642.05. Following the sale, the director now directly owns 137,396 shares of the company’s stock, valued at $3,785,259.80. The sale was disclosed in a document filed with the Securities and Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.93% of the company’s shares.

Hedge funds charge Agios Pharmaceuticals

Several large investors have recently increased or decreased their stake in the company. Mirae Asset Global Investments Co. Ltd. increased its position in Agios Pharmaceuticals by 0.8% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 314 shares during the period. CANADA LIFE ASSURANCE Co. increased its position in Agios Pharmaceuticals by 1.8% in the first quarter. CANADA LIFE ASSURANCE Co after purchasing an additional 540 shares during the period now owns 31,144 shares of the biopharmaceutical company’s stock valued at $911,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Agios Pharmaceuticals by 9.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 942 shares during the period. ProShare Advisors LLC increased its position in Agios Pharmaceuticals by 9.0% during the first quarter. ProShare Advisors LLC now owns 13,917 shares of the biopharmaceutical company’s stock valued at $407,000 after purchasing an additional 1,152 shares during the period. Finally, Rhumbline Advisers increased its holdings in Agios Pharmaceuticals by 1.2% in the third quarter. Rhumbline Advisers now owns 102,122 shares of the biopharmaceutical company’s stock valued at $2,528,000 after acquiring an additional 1,240 shares in the last quarter.

About Agios Pharmaceuticals

(Get the free report)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops cellular metabolism therapeutics in the United States. Its lead product is PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used to treat hemolytic anemia.

Agios Pharmaceuticals Price Performance

Confidential activity

Hedge funds charge Agios Pharmaceuticals

About Agios Pharmaceuticals

Further reading